Latest Blogs
-
Kim and Todd Saxton: Go for the gold! But maybe not every time.
-
Q&A: What you need to know about the CDC’s new mask guidance
-
Carmel distiller turns hand sanitizer pivot into a community fundraising platform
-
Lebanon considering creating $13.7M in trails, green space for business park
-
Local senior-living complex more than doubles assisted-living units in $5M expansion
CALPERS, the big pension fund, doesnâ??t want
Eli Lilly and Co.â??s new CEO, John Lechleiter, to be voted onto the board at Lillyâ??s annual meeting on Monday.
Lechleiter was a high-level player within Lilly in recent years while the companyâ??s stock performed at mediocre levels, CALPERS
says.
Is Lechleiter the problem?
Or is he being blamed for any problems that his predecessor, Sidney Taurel, might have created, or even for the overall sluggishness
in the pharmaceutical industry?
What do you think?
Please enable JavaScript to view this content.